Involvement of circulating platelets on the hyperalgesic response evoked by carrageenan and Bothrops jararaca snake venom

Imagem de Miniatura
Arquivos
art_YAMASHITA_Involvement_of_circulating_platelets_on_the_hyperalgesic_response_2011.PDF (325.24 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
NOGUEIRA, T. O.
SENISE, L. V.
CIRILLO, M. C.
GONCALVES, L. R. C.
SANO-MARTINS, I. S.
GIORGI, R.
Citação
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, v.9, n.10, p.2057-2066, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The role of platelets in hemostasis is well known, but few papers have reported their role in pain and edema induced by inflammatory agents. Objective: To evaluate the role of circulating platelets in the local injury induced by two diverse inflammatory agents, Bothrops jararaca venom (Bjv) and carrageenan. Methods: Rats were (i) rendered thrombocytopenic by administration of polyclonal anti-rat platelet IgG (ARPI) or busulfan, or (ii) treated with platelet inhibitors (aspirin or clopidogrel). Edema formation, local hemorrhage and the pain threshold were assessed after intraplantar injection of Bjv or carrageenan in rat hind paws. Additionally, whole platelets or platelet releasate were tested whether they directly induced hyperalgesia. Results: Platelet counts were markedly diminished in rats administered with either ARPI (+/- 88%) or busulfan (+/- 96%). Previous treatment with ARPI or busulfan slightly reduced edema induced by Bjv or carrageenan. Injection of Bjv, but not of carrageenan, induced a statistically significance increase in hemorrhage in the hind paws of thrombocytopenic rats. Remarkably, hyperalgesia evoked by Bjv or carrageenan was completely blocked in animals treated with ARPI or busulfan, or pre-treated with aspirin or clopidogrel. On the other hand, intraplantar administration of whole platelets or platelet releasate evoked hyperalgesia, which was inhibited by pre-incubation with alkaline phosphatase. Conclusions: Thrombocytopenia or inhibition of platelet function drastically reduced hyperalgesia induced by injection of carrageenan or Bjv; moreover, platelets per se secrete phosphorylated compounds involved in pain mediation. Thus, blood platelets are crucial cells involved in the pain genesis, and their role therein has been underestimated.
Palavras-chave
ATP, bleeding, carrageenan, inflammation, pain, polyphosphate, snake venom
URI
https://observatorio.fm.usp.br/handle/OPI/23552
Referências
  1. SANTORO ML, 1994, PLATELETS, V5, P162, DOI 10.3109/09537109409005530
  2. Cunha TM, 2008, J LEUKOCYTE BIOL, V83, P824, DOI 10.1189/jlb.0907654
  3. Yang C, 1999, BRIT J HAEMATOL, V105, P478, DOI 10.1046/j.1365-2141.1999.01359.x
  4. Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102
  5. Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514
  6. Krijgsveld J, 2000, J BIOL CHEM, V275, P20374, DOI 10.1074/jbc.275.27.20374
  7. Hilliges M, 2002, PAIN, V98, P59, DOI 10.1016/S0304-3959(01)00469-9
  8. Muller F, 2009, CELL, V139, P1143, DOI 10.1016/j.cell.2009.11.001
  9. Oliveira MCG, 2009, PAIN, V141, P127, DOI 10.1016/j.pain.2008.10.024
  10. Fusaro MCGD, 2010, EUR J PHARMACOL, V649, P177, DOI 10.1016/j.ejphar.2010.09.037
  11. Goncalves LRC, 2000, MEDIAT INFLAMM, V9, P101
  12. Cunha TM, 2007, EUR J PHARMACOL, V573, P221, DOI 10.1016/j.ejphar.2007.07.007
  13. May AE, 2008, ARTERIOSCL THROM VAS, V28, pS5, DOI 10.1161/ATVBAHA.107.158915
  14. Goerge T, 2008, BLOOD, V111, P4958, DOI 10.1182/blood-2007-11-123620
  15. WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
  16. Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928
  17. Ando RD, 2010, BRIT J PHARMACOL, V159, P1106, DOI 10.1111/j.1476-5381.2009.00596.x
  18. GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46
  19. TAIWO YO, 1990, BRAIN RES, V537, P372, DOI 10.1016/0006-8993(90)90389-S
  20. Tamagawa-Mineoka R, 2007, AM J PATHOL, V170, P2019, DOI 10.2353/ajpath.2007.060881
  21. Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008
  22. Lacci Kathleen M., 2010, Yale Journal of Biology and Medicine, V83, P1
  23. MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3
  24. Okuse K, 2007, INT J BIOCHEM CELL B, V39, P490, DOI 10.1016/j.biocel.2006.11.016
  25. Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011
  26. Santoro ML, 2008, TOXICON, V51, P1440, DOI 10.1016/j.toxicon.2008.03.018
  27. ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
  28. Fujimi S, 2006, BLOOD, V107, P4399, DOI 10.1182/blood-2005-09-3776
  29. Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309
  30. RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
  31. Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044
  32. Ruiz FA, 2004, J BIOL CHEM, V279, P44250, DOI 10.1074/jbc.M406261200
  33. Baldo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000727
  34. Blunk J, 1999, EUR J PAIN-LONDON, V3, P247, DOI 10.1016/S1090-3801(99)90052-6
  35. BLUNK JA, 2010, EUR J PAIN, V15, P23
  36. Brauer RB, 2003, TRANSPLANT INT, V16, P37, DOI 10.1007/S00147-002-0504-z
  37. BRAUNSTEIN PW, 1980, AM J PATHOL, V99, P53
  38. CARDOSO JLC, 1993, Q J MED, V86, P315
  39. CATTANEO M, 1985, THROMB RES, V37, P29, DOI 10.1016/0049-3848(85)90030-1
  40. Chacur M, 2002, TOXICON, V40, P1047, DOI 10.1016/S0041-0101(02)00089-2
  41. CURY Y, 1994, TOXICON, V32, P1425, DOI 10.1016/0041-0101(94)90414-6
  42. FAGAN JM, 1986, P NATL ACAD SCI USA, V83, P2771, DOI 10.1073/pnas.83.8.2771
  43. FERREIRA SH, 1976, AGENTS ACTIONS, V6, P313, DOI 10.1007/BF01972248
  44. Fu LW, 2002, AM J PHYSIOL-HEART C, V282, pH100
  45. HANDWERKER HO, 1999, PAIN NEUROGENIC INFL, P39
  46. KAMIGUTI AS, 1991, TOXICON, V29, P961, DOI 10.1016/0041-0101(91)90079-7
  47. Kapetanovic IM, 2009, CHEM-BIOL INTERACT, V179, P233, DOI 10.1016/j.cbi.2008.10.008
  48. Lauritzen B, 2009, J THROMB HAEMOST, V7, P651, DOI 10.1111/j.1538-7836.2009.03287.x
  49. LIN AH, 1989, J BIOL CHEM, V264, P17379
  50. Morris JC, 2003, METHOD MOL BIOL, V225, P115
  51. RINGKAMP M, 1994, NEUROSCI LETT, V170, P103, DOI 10.1016/0304-3940(94)90249-6
  52. Rocha SLG, 2000, TOXICON, V38, P875, DOI 10.1016/S0041-0101(99)00190-7
  53. Santoro ML, 2004, THROMB HAEMOSTASIS, V92, P369, DOI 10.1160/TH04-02-0120
  54. Schmelz M, 1997, NEUROSCI LETT, V226, P171, DOI 10.1016/S0304-3940(97)00269-3
  55. SHEPRO D, 1984, THROMB RES, V35, P421, DOI 10.1016/0049-3848(84)90234-2
  56. STUART MJ, 1975, NEW ENGL J MED, V292, P1310, DOI 10.1056/NEJM197506192922502
  57. TEIXEIRA CFP, 1994, TOXICON, V32, P419, DOI 10.1016/0041-0101(94)90293-3
  58. TREBIEN HA, 1989, AGENTS ACTIONS, V26, P292, DOI 10.1007/BF01967293
  59. TSCHOPP TB, 1972, BLOOD-J HEMATOL, V40, P217
  60. UBATUBA FB, 1975, AGENTS ACTIONS, V5, P31, DOI 10.1007/BF02027155
  61. VINEGAR R, 1976, FED PROC, V35, P2447
  62. WU KK, 1988, J BIOL CHEM, V263, P19043

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros